Early results from clinical trials on substances like MDMA and psilocybin have been encouraging. In the middle of what is often regarded as a mental health crisis, many of these initiatives target a few of the most expensive and challenging mental health conditions while they are still happening. Researchers and executives discussed how that might convince health insurers, or “payors,” to jump on board during a Perspective on Psychedelics conference in New York.
Get ready for Deep Stories’ CannaLand! Arizona’s premier one-day cannabis festival begins 11 a.m. on…
They sit in circles, eyes gleaming with hope as they declare, "If I could only…
In a move that surprised absolutely no one who's been paying attention, the White House…
The NBA champion and New York Knick will premier his new flower brand at Torches…
By: LMC Legacy to licensed is the motto for authentic New York brands entering the…
Vlad Bautista began his cannabis empire in Harlem's Sugar Hill. Nearly 30 years later, his…